Dyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report) reached a new 52-week low during mid-day trading on Wednesday . The company traded as low as $10.88 and last traded at $10.91, with a volume of 377079 shares changing hands. The stock had previously closed at $11.40.
Wall Street Analysts Forecast Growth
A number of research firms have recently weighed in on DYN. HC Wainwright reiterated a "buy" rating and issued a $46.00 price target on shares of Dyne Therapeutics in a research report on Monday, March 17th. BMO Capital Markets started coverage on shares of Dyne Therapeutics in a research report on Wednesday, March 12th. They set an "outperform" rating and a $50.00 price objective for the company. Robert W. Baird started coverage on shares of Dyne Therapeutics in a research note on Friday, December 13th. They set an "outperform" rating and a $46.00 price objective on the stock. Royal Bank of Canada restated an "outperform" rating and issued a $45.00 target price on shares of Dyne Therapeutics in a research report on Tuesday, January 14th. Finally, Raymond James upgraded Dyne Therapeutics to a "strong-buy" rating in a research note on Thursday, December 12th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, twelve have assigned a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $47.46.
Get Our Latest Analysis on Dyne Therapeutics
Dyne Therapeutics Stock Performance
The business's fifty day moving average is $13.27 and its 200-day moving average is $23.45. The firm has a market cap of $1.30 billion, a P/E ratio of -3.22 and a beta of 1.11.
Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last issued its quarterly earnings data on Tuesday, March 4th. The company reported ($0.88) earnings per share for the quarter, topping the consensus estimate of ($0.92) by $0.04. Analysts predict that Dyne Therapeutics, Inc. will post -3.44 EPS for the current fiscal year.
Insider Activity
In other news, insider Oxana Beskrovnaya sold 2,598 shares of the stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $13.95, for a total transaction of $36,242.10. Following the completion of the sale, the insider now directly owns 199,087 shares in the company, valued at $2,777,263.65. This represents a 1.29 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Over the last quarter, insiders sold 6,237 shares of company stock valued at $77,760. Company insiders own 20.77% of the company's stock.
Institutional Trading of Dyne Therapeutics
Large investors have recently bought and sold shares of the business. Quantbot Technologies LP acquired a new position in Dyne Therapeutics in the third quarter valued at approximately $34,000. Point72 DIFC Ltd bought a new position in shares of Dyne Therapeutics during the 3rd quarter worth about $36,000. GF Fund Management CO. LTD. acquired a new stake in shares of Dyne Therapeutics in the 4th quarter valued at about $50,000. KBC Group NV increased its position in Dyne Therapeutics by 45.3% in the 4th quarter. KBC Group NV now owns 3,135 shares of the company's stock valued at $74,000 after buying an additional 978 shares in the last quarter. Finally, Summit Investment Advisors Inc. raised its stake in Dyne Therapeutics by 9.1% during the 4th quarter. Summit Investment Advisors Inc. now owns 8,627 shares of the company's stock worth $203,000 after buying an additional 721 shares during the period. 96.68% of the stock is currently owned by institutional investors and hedge funds.
About Dyne Therapeutics
(
Get Free Report)
Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.
Further Reading
Before you consider Dyne Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dyne Therapeutics wasn't on the list.
While Dyne Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
